Establishment of an novel reversal of anticancer drug resistance based on the epigenetic information

2016 Fiscal Year Final Research Report

• Project/Area Number: 26460246
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Himeji Dokkyo University
• Principal Investigator: Takara Kohji 姫路獨協大学, 薬学部, 教授 (00329939)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: エピジェネティクス / 癌 / 抗癌剤耐性

Outline of Final Research Achievements

The various types of mechanism are participated in the phenomena which shows the resistance to anticancer drugs in cancer cells. Herein, from the viewpoints of epigenetics causing the change in the gene function, the relation with the drug resistance and epigenetics were examined. As results, the differences in the global DNA methylation were not found in HeLa and its resistant cells. However, the expressions of mRNA involving in the epigenetics were different among the cells. Treatment with drugs having the activity of demethylation increased sensitivity to cisplatin in either cells. Consequently, the novel possibility of reversal of resistance may be demonstrated, although the relation with the drug resistance and epigenetics has not reached the sufficient evidence.

Free Research Field

医療薬剤学